Sign In
Buy RFL
$1.35
-0.0200 (-1.46%)
At Close: Jun 03, 2026
Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08
05:00pm, Friday, 16'th Apr 2021
NEWARK, N.J., April 16, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), today announced that on April 15, 2021 it made a grant to William Conkling of options to purchase 118,409 shares of Cla
Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results
04:30pm, Wednesday, 17'th Mar 2021
NEWARK, N.J., March 17, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.0 million and a loss per share of $0.50 for the second quarter of its 2021 fiscal year, the thr
Rafael Holdings Enhances Senior Management Team with Additions of Ameet Mallik, CEO and William Conkling, CCO
05:00pm, Thursday, 11'th Mar 2021
NEWARK, N.J., March 11, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), today announced that its Board of Directors has recruited Ameet Mallik to become the company's Chief Executive Officer
Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference
11:30am, Tuesday, 19'th Jan 2021
President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wed
Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
09:00am, Wednesday, 13'th Jan 2021
CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announc
CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced tod
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today anno
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announc
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
09:00am, Tuesday, 10'th Nov 2020
CRANBURY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced tod
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma
09:30am, Thursday, 29'th Oct 2020
Company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue sarcoma, in the coming months Company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue sarcoma,
